• Home
  • Study Details
By physician referral or invitation only

N-803 With and Without Combination bNAbs

The purpose of this study is to investigate if N-803, a new experimental drug that stimulates the immune system, is safe and tolerable when given alone and in combination with two new experimental drugs that are antibodies (natural proteins that the body makes in response to an infection) to HIV (the virus that causes AIDS), VRC07-523LS and 10-1074. This study will also look at how well HIV is controlled after stopping anti-HIV medications (also known as "ART") in persons who received N-803 alone or N-803 with VRC07-523LS and 10-1074.

Age & Gender

  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

David Wohl
Medicine-Infectious Diseases

Study Type

Clinical or Medical
Interventional

Study Topics

HIV/AIDS

IRB Number

21-0056

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research